The implementation of molecular tumor profiling in the practice of pediatric cancer pathology: The pathologists' experience.
Molecular
neoplasm
pediatric
survey
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
10 Oct 2024
10 Oct 2024
Historique:
revised:
06
09
2024
received:
05
08
2024
accepted:
23
09
2024
medline:
13
10
2024
pubmed:
13
10
2024
entrez:
10
10
2024
Statut:
aheadofprint
Résumé
The increased accessibility and utilization of molecular testing including next-generation sequencing (NGS) has impacted the practice of pediatric pathology, with diagnostic, prognostic, and therapeutic implications for our patients. This survey is the first to describe the utilization of molecular testing in the routine practice of pediatric pathology for the care of children with known or suspected solid tumors. The Society for Pediatric Pathology Practice Committee distributed a survey to our membership asking 25 questions about training, practice setting, molecular ordering practices, and barriers to testing. Seventy-five pathologists responded to the survey. The survey provides valuable insight into the current use of molecular testing for the care of children with known or suspected solid tumors. Most respondents reported that they are increasingly using a variety of molecular techniques, with increased use over time, and that NGS is useful. These results highlight a variety of barriers to molecular testing, including cost, insurance coverage, turnaround time, limitations of available assays (including limited coverage of pediatric-specific alterations), and difficulty in determining the most appropriate test to order. These data may be useful in supporting pediatric pathologists in their practice.
Sections du résumé
BACKGROUND
BACKGROUND
The increased accessibility and utilization of molecular testing including next-generation sequencing (NGS) has impacted the practice of pediatric pathology, with diagnostic, prognostic, and therapeutic implications for our patients. This survey is the first to describe the utilization of molecular testing in the routine practice of pediatric pathology for the care of children with known or suspected solid tumors.
PROCEDURE
METHODS
The Society for Pediatric Pathology Practice Committee distributed a survey to our membership asking 25 questions about training, practice setting, molecular ordering practices, and barriers to testing.
RESULTS
RESULTS
Seventy-five pathologists responded to the survey. The survey provides valuable insight into the current use of molecular testing for the care of children with known or suspected solid tumors. Most respondents reported that they are increasingly using a variety of molecular techniques, with increased use over time, and that NGS is useful.
CONCLUSIONS
CONCLUSIONS
These results highlight a variety of barriers to molecular testing, including cost, insurance coverage, turnaround time, limitations of available assays (including limited coverage of pediatric-specific alterations), and difficulty in determining the most appropriate test to order. These data may be useful in supporting pediatric pathologists in their practice.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e31370Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
NCCN. Non‐small cell lung cancer (version 3.2024). Accessed March 31, 2024, https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
NCCN. Soft tissue sarcoma (version 3.2023). Accessed March 31, 2024, https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf
NCCN. Neuroblastoma (version 1.2024). Accessed March 31, 2024, https://www.nccn.org/professionals/physician_gls/pdf/neuroblastoma.pdf
Parsons DW, Patton DR, Winter CL, et al. Actionable tumor alterations and treatment protocol enrollment of pediatric and young adult patients with refractory cancers in the National Cancer Institute‐Children's Oncology Group Pediatric MATCH Trial. J Clin Oncol. 2022;40(20):2224‐2234.
Harttrampf AC, Deloger M, Deschamps F, et al. Molecular screening for cancer treatment optimization (MOSCATO‐01) in pediatric patients: a single‐institutional prospective molecular stratification trial. Clin Cancer Res. 2017;23(20):6101‐6112.
Sholler GLS, Bergendahl G, Lewis EC, et al. Molecular‐guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial. Genome Med. 2024;16(1):28.
Church AJ, Kao PC, Imamovic‐Tuco A, et al. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med. 2022;28(8):1581‐1589.
Implentation science—opportunities in cancer research. Accessed March 31, 2024, https://www.cancer.gov/research/areas/treatment/implementation‐science
Roberts MC, Spees LP, Freedman AN, et al. Oncologist‐reported reasons for not ordering multimarker tumor panels: results from a nationally representative survey. JCO Precis Oncol. 2021;5. PO.20.00431.
WHO classification of tumours editorial board. Paediatric tumours. 5 ed. vol 7. International Agency for Research on Cancer; 2022.